Vinati Organics Ltd Q3 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/goc30xsv0iubtgzi8wgstx6m.pdf

Key Takeaways


ATBS: Destocking, Pricing & Market Position

Mutreja: "I think based on the demand outlook as well as the order book, you will see recovery, if not from Feb, March, definitely from April."

Antioxidants: The Growth Story

Mutreja: "No, no, no. This INR100 to INR120 crores will be the antioxidant revenue in this entire financial year FY24. Then, next year I expect this revenue to double from INR120 to about INR250 crores."

Veeral Additives: From Dilutive to Accretive

Mutreja: "So, eventually, this from being value diluting, we hope for it to become value-attractive in the next six months or so."

New Product Pipeline & Capex


Margins & Balance Sheet

Mutreja: "Those margins were never sustainable. That is, you come across those golden periods few times as a manufacturer in any manufacturing business. And I always have maintained that on a long-term basis, margins around 27% for any manufacturing business is a decent margin."

Revenue Mix & Segment Trends


Guidance & Commitments

CommitmentSpecificsTimeline
ATBS demand recoveryRecovery visible in order book and demand outlookIf not Feb/March, definitely from April
ATBS capacity expansionExpansion from 40,000 to 60,000 tonnes completedDecember 2024
Antioxidant revenueDouble from ₹100-120 cr to ~₹250 crFY25
Antioxidant full utilizationReach full capacity utilization2-3 years
Veeral Additives value accretionBecome value-attractiveNext 6 months
MEHQ-Guaiacol plantCommissionedMarch 2024
VOPL other products4-MAP, isoamylene derivatives, anisole commissionedH2 FY25
Revenue CAGR15-20% CAGR, reaching ~₹3,000 cr3-5 years
Sustainable EBITDA margin25-27% blendedLong-term

Key Metrics

MetricQ3 FY24
Total income₹457 cr, down 4% QoQ from ₹473 cr
EBITDA₹124 cr, up 7% QoQ from ₹115 cr
Profit after tax₹77 cr, up 6% QoQ from ₹72 cr
EBITDA margin27%, improved from 24% in Q2 FY24
Revenue CAGR guidance15% to 20% over the next three years
ATBS revenue share30% of total income for the quarter, 32% for 9M FY24
IBB revenue share20% of total income for the quarter, 18% for 9M FY24
Butylphenols and IB derivatives revenue share20% of total income
Isobutylene revenue share10% of total income
Antioxidant and other products revenue share20% of total income
Antioxidant revenue₹100 cr to ₹120 cr expected for full FY24, at 25% capacity utilization
Antioxidant revenue guidance~₹250 cr expected for FY25, doubling from FY24
ATBS capacity utilization60% to 65% on present 40,000-tonne capacity over 9M FY24
IBB capacity utilization~65% for the year
ATBS market share~65%
ATBS price$3.2–$3.3, management-corrected range
Customized products scale-up₹150 cr, doubled from ₹75 cr over the last couple of years
OSBP and DSBP revenue potential₹80 cr at full capacity
VOPL total capex₹480 cr for the basket of 5–6 niche specialty chemical products
New projects expected ROI15% to 20%
New projects blended margin~20%
MEHQ and Guaiacol combined capacity3,000 tonnes per annum, 2,000 tonnes MEHQ and 1,000 tonnes Guaiacol
Anisole capacity5,000 tonnes
4-MAP capacity1,000 tonnes
TAA and PTAP combined capacity~10,000 tonnes
MEHQ and Guaiacol plant commissioningMarch 2024
Other VOPL products commissioningSecond half of FY25, around December 2024
ATBS expansion completionDecember 2024, capacity rising from 40,000 to 60,000 tonnes
Solar power capacity added in FY2411 megawatts, taking total to 26 megawatts; another 7 megawatts planned in Q4 FY25
Capex in current year₹240 cr to ₹300 cr
Capex for FY25₹450 cr to ₹500 cr
Gross block addition from Veeral Additives amalgamation~₹300 cr
Depreciation from Veeral Additives~₹15 cr per year
Interest income knocked off from Veeral Additives loan₹32 cr over the last two years
Long-term debtNil, no working capital debt on books
Sustainable EBITDA margin guidance25% to 27% on a blended level
Revenue in 4–5 years~₹3,000 cr (per management), ~₹3,500 cr (per an analyst's math)